Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 2/20 | 0.50 |
| ▸ | LTA4H | P09960 | 5/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL438114 | 0.90 | PLK1 (0.44) | FAAHLTA4HTP53PTGS2 | |
| SCHEMBL437666 | 0.89 | L3MBTL1 (0.49) | LTA4HPTGS2PDK2 | |
| SCHEMBL38664 | 0.75 | LTA4H (0.60) | LTA4HPOLBSMN1; SMN2 | |
| SCHEMBL438258 | 0.73 | ALDH1A1 (0.62) | TP53POLBSMN1; SMN2 | |
| SCHEMBL10205950 | 0.72 | PLK1 (0.54) | PTGS2POLB | |
| SCHEMBL7048969 | 0.72 | FAAH (0.63) | FAAHLTA4HTP53 | |
| SCHEMBL435644 | 0.71 | RXRA (0.58) | FAAHTP53SMN1; SMN2 | |
| SCHEMBL436572 | 0.71 | FABP4 (0.55) | TP53SMN1; SMN2 | |
| SCHEMBL14280209 | 0.71 | HTT (0.55) | SMN1; SMN2 | |
| SCHEMBL5922429 | 0.70 | CHRNA7 (0.73) | TP53POLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065241-A1 | THERAPEUTIC COMPOUNDS FOR DISEASES AND DISORDERS | MYREXIS, INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-20120065241-A1 | THERAPEUTIC COMPOUNDS FOR DISEASES AND DISORDERS | MYREXIS, INC. (US) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065241-A1 | THERAPEUTIC COMPOUNDS FOR DISEASES AND DISORDERS | NLN, SLC18A2, GOLT1B | FAAH 2378/4885LTA4H 2911/4885TP53 3708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.